Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPO-140
- Development stage
- Unknown
- Lead developer
- Conjupro Biotherapeutics
- Modality
- Nanoparticles → Drug Delivery Systems, Small Molecules
- Administration
- Intravenous
01
Overview
CPO-140 is a liposomal formulation of the anthracycline antineoplastic agent doxorubicin, developed by CONJ Biotherapeutics. Doxorubicin exerts its cytotoxic effects by intercalating into DNA and inhibiting the enzyme topoisomerase II, which prevents the religation of DNA strands and leads to DNA damage and apoptosis. The liposomal delivery system is designed to optimize the pharmacokinetic profile of doxorubicin, potentially enhancing its accumulation in tumor tissues through the enhanced permeability and retention (EPR) effect while minimizing systemic toxicities, particularly cardiotoxicity. CPO-140 is being developed as a potential generic or improved formulation (ANDA/NDA pathway) for the treatment of various solid and liquid tumors and is currently in the Pre-NDA/ANDA stage.
- Other names
- Liposomal Doxorubicin
02
Targets
TOP2A (DNA topoisomerase II)DNA
Beyond the preview
Go deeper on CPO-140.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPO-140.